![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Allergan |
---|---|
Information provided by: | Allergan |
ClinicalTrials.gov Identifier: | NCT00076687 |
The purpose of this study is to evaluate the safety of injections of botulinum toxin Type A in patients with reduced lung function and focal upper limb poststroke spasticity
Condition | Intervention | Phase |
---|---|---|
Stroke Muscle Spasticity Motor Neuron Disease |
Biological: botulinum toxin Type A Drug: saline |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety Study |
Estimated Enrollment: | 150 |
Study Start Date: | October 2003 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Biological: botulinum toxin Type A
botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
|
2: Experimental |
Biological: botulinum toxin Type A
botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
|
3: Placebo Comparator |
Drug: saline
Saline injection at Day 1, Week 12, Week 18
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Abnormal pulmonary function test results; focal, upper limb spasticity, upper motor neuron syndrome
Exclusion Criteria:
- Previous exposure to botulinum toxin of any serotype
Contact: Allergan Inc. | clinicaltrials@allergan.com |
United States, Florida | |
Recruiting | |
Miami, Florida, United States | |
Czech Republic | |
Recruiting | |
Prague, Czech Republic | |
Hungary | |
Recruiting | |
Szeged, Hungary | |
Poland | |
Enrolling by invitation | |
Warsaw, Poland |
Study Director: | Medical Director | Allergan |
Responsible Party: | Allergan, Inc. ( Therapeutic Area Head ) |
Study ID Numbers: | 191622-057 |
Study First Received: | January 29, 2004 |
Last Updated: | December 5, 2008 |
ClinicalTrials.gov Identifier: | NCT00076687 |
Health Authority: | United States: Food and Drug Administration |
Cerebral Infarction Stroke Vascular Diseases Central Nervous System Diseases Degenerative motor system disease Neurodegenerative Diseases Brain Diseases Motor neuron disease Cerebrovascular Disorders Signs and Symptoms |
Muscle Spasticity Botulinum Toxins Muscular Diseases Neuromuscular Diseases Musculoskeletal Diseases Muscle Hypertonia Neurologic Manifestations Botulinum Toxin Type A Motor Neuron Disease |
Neuromuscular Manifestations Anti-Dyskinesia Agents Therapeutic Uses Physiological Effects of Drugs Nervous System Diseases |
Neuromuscular Agents Cardiovascular Diseases Peripheral Nervous System Agents Central Nervous System Agents Pharmacologic Actions |